Uni-Bio Science Group Ltd
HKEX:690
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.052
0.165
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| HK |
|
Uni-Bio Science Group Ltd
HKEX:690
|
644.9m HKD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.7B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.1B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.5B USD |
Loading...
|
Market Distribution
| Min | -36 930 000% |
| 30th Percentile | -5.1% |
| Median | 2.5% |
| 70th Percentile | 9.4% |
| Max | 8 238.3% |
Other Profitability Ratios
Uni-Bio Science Group Ltd
Glance View
Uni-Bio Science Group Ltd. is an investment holding company with interests in pharmaceutical research and development. The company employs 326 full-time employees The company went IPO on 2001-11-12. The firm operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Uni-Bio Science Group Ltd is 17%, which is above its 3-year median of 15.7%.
Over the last 3 years, Uni-Bio Science Group Ltd’s Operating Margin has increased from 2.7% to 17%. During this period, it reached a low of 2.7% on Jun 30, 2022 and a high of 20.6% on Jun 30, 2024.